Avibactam

Summary

Avibactam (CHEMBL1689063) is an approved small-molecule antibacterial drug; indicated across 8 conditions including pneumonia and bacterial infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 8 conditions
• Clinical trials: 8
• Chemistry: 265.25 Da · C7H11N3O6S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1689063
Name	Avibactam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	9835049
ChEBI	CHEBI:85984
Molecular formula	C7H11N3O6S
Molecular weight	265.25
InChIKey	NDCUAPJVLWFHHB-UHNVWZDZSA-N

SMILES: C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)N

IUPAC name: [(2S,5R)-2-carbamoyl-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate

ChEBI definition: A member of the class of azabicycloalkanes that is (2S,5R)-7-oxo-1,6-diazabicyclo[3.2.1]octane-2-carboxamide in which the amino hydrogen at position 6 is replaced by a sulfooxy group. Used (in the form of its sodium salt) in combination with ceftazidime pentahydrate for the treatment of complicated urinary tract infections including pyelonephritis.

Pharmacological roles (ChEBI): antibacterial drug, antimicrobial agent, EC 3.5.2.6 (β-lactamase) inhibitor.

Also known as: Avibactam, Avibactam component of zavicefta, Nxl-104, Nxl-104 free acid, AVIBACTAM, Avibactam (sodium), avibactam

Parent form; salt/anhydrous children: CHEMBL2107817

Patent coverage: 581 distinct patent families (1,178 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,176 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 7 (assay-derived). Sample: Metallo-beta-lactamase type 2, Beta-lactamase TEM, Beta-lactamase, Beta-lactamase OXA-23, Beta-lactamase OXA-1, Beta-lactamase, Carbapenem-hydrolyzing beta-lactamase KPC.

Bioactivity

ChEMBL activities: 10 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62593	8.72	IC50	1.9	nM	CHEMBL_ACT_23183621
P05364	7	IC50	100	nM	CHEMBL_ACT_5298798
P13661	6.89	IC50	130	nM	CHEMBL_ACT_25498504
P24735	6.89	IC50	128	nM	CHEMBL_ACT_5298799
P14488	6.85	IC50	141.1	nM	CHEMBL_ACT_25095745
Q9F663	6.73	IC50	186	nM	CHEMBL_ACT_25498500
P05364	6.04	IC50	923	nM	CHEMBL_ACT_25498502
Q9L4P2	5.77	Ki	1700	nM	CHEMBL_ACT_20658851
Q9L4P2	5.63	IC50	2320	nM	CHEMBL_ACT_25498508
P05364	5.11	Ki	7700	nM	CHEMBL_ACT_5298805

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
pneumonia	3	MONDO:0005249	EFO:0003106
bacterial infectious disease	3	MONDO:0005113	EFO:0000771
pyelonephritis	3	MONDO:0006939	EFO:1001141
urinary tract infection	2	MONDO:0100338	EFO:0003103
gram-negative bacterial infections	2	MONDO:0021678	MONDO:0021678
kidney failure	1	MONDO:0001106	HP:0000083

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	5
PHASE4	1
PHASE2	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02504827	PHASE4	COMPLETED	Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis
NCT07431307	PHASE2	NOT_YET_RECRUITING	Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex
NCT01430910	PHASE1	COMPLETED	A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately
NCT01689207	PHASE1	COMPLETED	To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)
NCT02822950	PHASE1	COMPLETED	A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients
NCT05588531	PHASE1	COMPLETED	Study on Tolerance, Pharmacokinetics and Drug Interaction of YK-1169 in Healthy Volunteers
NCT06593054	PHASE1	COMPLETED	To Learn How Different Forms of Study Medicine Are Taken up Into the Blood and the Effect of Food on Study Medicine in Healthy Adults
NCT06210542	Not specified	NOT_YET_RECRUITING	Precise Treatment of Ceftazidime-Avibactam in Patients With CRO Infections Under the Guidance of TDM and PPK Model

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).